ANI Pharmaceuticals, Inc. filed a Form 8-K on August 24, 2026, reporting the appointment of Henry Gosebruch to its Board of Directors and the resignation of Muthusamy "Samy" Shanmugam from the Board, both effective August 2026.

Key Highlights

  • New director appointed: Henry Gosebruch, age 53, was appointed to the ANI Pharmaceuticals Board of Directors on August 19, 2026, with a term expiring at the 2027 annual meeting of stockholders.
  • Initial equity grant: Gosebruch will receive a restricted stock award under the Amended and Restated 2022 Stock Incentive Plan with a grant date fair value of $525,000, vesting in three equal installments on the first, second, and third anniversaries of joining the Board.
  • Gosebruch's current role: He has served as Chief Executive Officer and board member of Lakefront Biotherapeutics NV since May 2025.
  • Prior leadership: Gosebruch previously served as President and Chief Executive Officer of Neumora Therapeutics, Inc. from July 2023 to February 2025, and as Executive Vice President and Chief Strategy Officer at AbbVie Inc. from December 2015 to February 2023.
  • Director resignation: Muthusamy "Samy" Shanmugam resigned from the Board effective immediately on August 23, 2026, and will continue in his executive role as Head of Research and Development and Chief Operating Officer of New Jersey Operations.

Board Changes at ANI Pharmaceuticals: Gosebruch In, Shanmugam Steps Down as Director

According to the filing, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) disclosed two simultaneous Board of Directors changes on August 24, 2026. The Board appointed Henry Gosebruch as a director on August 19, 2026. His term is set to expire at the company's 2027 annual meeting of stockholders. The filing states there is "no arrangement or understanding between Mr. Gosebruch and any other person pursuant to which Mr. Gosebruch was selected to serve as a director of the Company."

As disclosed, Gosebruch brings experience spanning biotechnology leadership, corporate strategy, and investment banking. In addition to his current role at Lakefront Biotherapeutics NV, he previously held senior positions at Neumora Therapeutics, AbbVie, and J.P. Morgan, where the filing states he was "Co-Head of the North American M&A Group" after more than 20 years at the firm. His responsibilities at AbbVie reportedly included "corporate strategy, competitive intelligence, business development, and M&A." The filing also notes that Gosebruch is not a party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the company.

On August 23, 2026, Shanmugam informed the Board of his resignation as a director, effective immediately. The filing clarifies that Shanmugam will remain with the company in his executive capacity as Head of Research and Development and Chief Operating Officer of New Jersey Operations. The company issued a press release on August 24, 2026, announcing both changes, attached as Exhibit 99.1 to the filing.

What Was Disclosed

ANI Pharmaceuticals reported the appointment of Henry Gosebruch to its Board effective August 19, 2026, including a $525,000 restricted stock award, and the resignation of Samy Shanmugam as a director effective August 23, 2026, while Shanmugam retains his executive management roles.